Pyxis Oncology, Inc. (PYXS): Price and Financial Metrics

Pyxis Oncology, Inc. (PYXS): $2.49

0.05 (+2.05%)

POWR Rating

Component Grades













Add PYXS to Watchlist
Sign Up

Industry: Biotech



in industry

PYXS Stock Price Chart Interactive Chart >

Price chart for PYXS

PYXS Price/Volume Stats

Current price $2.49 52-week high $19.00
Prev. close $2.44 52-week low $1.96
Day low $2.39 Volume 144,400
Day high $2.51 Avg. volume 135,646
50-day MA $3.20 Dividend yield N/A
200-day MA $0.00 Market Cap 81.71M

Pyxis Oncology, Inc. (PYXS) Company Bio

Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

PYXS Latest News Stream

Event/Time News Detail
Loading, please wait...

PYXS Latest Social Stream

Loading social stream, please wait...

View Full PYXS Social Stream

Latest PYXS News From Around the Web

Below are the latest news stories about Pyxis Oncology Inc that investors may wish to consider to help them evaluate PYXS as an investment opportunity.

Quite a few insiders invested in Pyxis Oncology, Inc. (NASDAQ:PYXS) last year which is positive news for shareholders

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Yahoo | January 10, 2022

Dogness, Axcelis lead aftermarket gainers; Pyxis Oncology among losers

Gainers: Dogness (DOGZ) +17%, Axcelis Technologies (ACLS) +6%, Latch (LTCH) +5%, Faraday Future Intelligent Electric (FFIE) +3%, BigCommerce (BIGC) +3%.Losers: Pyxis

Seeking Alpha | January 7, 2022

Pyxis to be Added to Russell 2000® Index

CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that the company will be added to the Russell 2000® Index, effective after the U.S. market opens on December 20, 2021, according to the preliminary list of IPO additions to the Russell indexes. Membership in the Russell 2000 Index, which remains in place until the next reconstitution, is based on membership in the broad-market Russell 3000® Index. The stock will also be automatically added to the appropriate growth and value indexes.

Intrado Digital Media | December 15, 2021

Darren S. Cline Acquires 10,000 Shares of Pyxis Oncology Inc (NASDAQ:PYXS) Stock

Pyxis Oncology Inc (NASDAQ:PYXS) Director Darren S. Cline bought 10,000 shares of the companys stock in a transaction dated Wednesday, December 8th. The stock was bought at an average price of $9.39 per share, for a total transaction of $93,900.00. The transaction was disclosed in a document filed with the SEC, which is available at []

Transcript Daily | December 11, 2021

Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer

Industry veteran brings expertise in corporate strategy and business development to Pyxis teamCAMBRIDGE, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced the appointment of Martina Molsbergen as Interim Chief Business Officer. Ms. Molsbergen will be responsible for managing the Company’s current partnerships and joint ventures as well as exploring new business development opportunities. “We are thrilled to welcome Martina to the Pyxis team as interim c

Yahoo | December 9, 2021

Read More 'PYXS' Stories Here

PYXS Price Returns

1-mo -8.12%
3-mo -60.16%
6-mo -80.30%
1-year N/A
3-year N/A
5-year N/A
YTD -77.30%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4787 seconds.